News and Trends

| June 12, 2012

Sleeve Gastrectomy With Transit Bipartition: A Potent Intervention for Metabolic Syndrome and Obesity
From Santoro S, Castro LC, Velhote MC, et al. Ann Surg. 2012 May 17. [Epub ahead of print]
In this article published in Annals of Surgery, the authors present five-year results of sleeve gastrectomy (SG) with transit bipartition (TB) as a metabolic intervention for obesity. A total of 1,020 patients with body mass indices (BMIs) ranging from 33 to 72kg/m2 underwent SG and TB. TB creates a gastroileal anastomosis in the antrum after the SG; nutrient transit is maintained in the duodenum, avoiding blind loops and minimizing malabsorption. The stomach retains two outflow pathways. A lateral enteroanastomosis connects both segments at 80cm proximal to the cecum.

Adequate follow-up data were collected in 59.1 percent of patients from 4 months to 5 years. The average percent of excess BMI loss was 91, 94, 85, 78, and 74 percent in the first, second, third, fourth, and fifth year, respectively. Patients experienced early satiety and major improvement in presurgical comorbidities, including diabetes (86% in remission), following surgery.

The authors concluded that SG plus TB is a simple procedure that results in rapid weight loss and remission or major improvement of comorbidities. Strictly aiming at physiological correction, TB avoids prostheses, narrow anastomoses, excluded segments, and malabsorption. Weight and comorbidities are much improved. Diabetes is improved without duodenal exclusion. TB is an excellent complement to an SG.

To read the full abstract, visit http://www.ncbi.nlm.nih.gov/pubmed/22609843

The Centers for Disease Control and Prevention Recognize Obesity Prevention and Control Initiatives with Pioneering Innovation Awards
Six organizations and one person are recipients of the Pioneering Innovation Award for their work in advancing policies and environmental strategies to prevent and control obesity. The awards were given at the Centers for Disease Control and Prevention (CDC) Weight of the Nation Conference in Washington, DC. The award recipients were recognized in the categories of systems change, community mobilization, game changer, applied obesity research, and moving forward with technology. This is the second time the awards have been given.
CDC stated that they recognizes the need for a variety of approaches to reverse the high rates of obesity, particularly among certain racial and ethnic groups.

“We are excited about the impressive group of award recipients and the commitment each has made to programs and policies that achieve measurable impact in preventing obesity,” said William H. Dietz, MD, PhD, director of CDC’s Division of Nutrition, Physical Activity, and Obesity. “There is much focus on what individuals can do to improve their health, and while that is important, we must remember our nation’s health is also strongly affected by environmental changes that result from the collective efforts of all sectors of society.”
An awards panel of representatives from numerous public health organizations chose the winners from more than 90 applications. Award recipients by category are as follows:

•    Systems Change Award—CATCH (Coordinated Approach to Child Health), an evidence-based primary prevention intervention, run out of the University of Texas School of Public Health’s Michael and Susan Dell Center for Healthy Living, to instruct children, their schools, and families in healthy eating and physical activity.

•    Community Mobilization Award—Dr. Antronette Yancey, professor at the UCLA School of Public Health. Dr. Yancey conceived the Instant Recess population physical activity promotion approach nearly 13 years ago as a way of integrating short bouts of easy-to-do exercise in workplaces, schools, churches, and sports arenas.

•    Game Changer Award—Safe Routes to School National Partnership, launched in 2005 by Deb Hubsmith, works to improve bicycle and pedestrian routes to schools in California.

•    Applied Obesity Research Award—The Robert Wood Johnson Foundation works with a diverse group of organizations and individuals to identify solutions and achieve comprehensive, measureable, and timely change.

•    Moving Forward with Technology Award—Community Commons, run out of the Center for Applied Research and Environmental Systems (CARES) at the College of Agriculture, Food and Natural Resources at the University of Missouri, is an interactive mapping, networking, and learning website for leaders from community to national levels, working to create healthy, equitable, and sustainable communities.

To read more, visit http://www.cdc.gov/media/releases/2012/p0509_obesity_prevention.html. For more information on the Weight of the Nation Conference, visit www.cdc.gov/won

VIVUS Says Decision On Approval Of Qnexa Is Pending
In April 2012, Vivus Inc., manufacturer of Qnexa, an investigational drug, taken orally for the treatment of obesity, submitted its response to the Day 180 List of Outstanding Issues. European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has scheduled an oral hearing in regards to the drug for September this year, and the CHMP opinion on Qnexa is expected to be released shortly after the meeting.

“We appreciate the flexibility of the CHMP to work with us on the timing of the oral hearing and the scheduling in September … We look forward to presenting to the CHMP in September, but are currently focused on working with the FDA ahead of the July 17, 2012 PDUFA and the potential Qnexa launch in the US in the second half of this year.”

Meanwhile, in the US, Vivus said it is focusing on working with the US Food and Drug Administration (FDA) in the run up to its July 17th meeting. Vivus said it expects approval of the drug and plans to begin full marketing of the drug in the later part of 2012. Qnexa is one of three obesity drugs pending approval, after the FDA initially rejected them, on grounds of harmful side effects, such as heart problems.

Jentadueto™ (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe
(Ingelheim, Germany)—Boehringer Ingelheim and Eli Lilly and Company announced that they have received a positive opinion from the European Medicines Agency’s (EMA) medicinal committee recommending approval of Jentadueto™, which combines the DPP-4 inhibitor, linagliptin (the active ingredient in Trajenta® tablets) and metformin in a single tablet.1 If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with type 2 diabetes mellitus (T2DM) who need to improve control of their blood glucose.[1] In clinical studies, linagliptin/metformin HCl demonstrated benefit to patients by offering another dosing option with effective glycaemic control and a favorable side effect profile.
1. Boehringer Ingelheim. Data on File.

For the full press release, visit http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/25_may_2012_diabetes.html

Category: News and Trends

Comments are closed.